OPKO Health, Inc. (NASDAQ:OPK) Vice Chairman Elias A. Zerhouni Acquires 89,600 Shares

OPKO Health, Inc. (NASDAQ:OPKGet Rating) Vice Chairman Elias A. Zerhouni purchased 89,600 shares of OPKO Health stock in a transaction dated Tuesday, May 10th. The stock was bought at an average price of $2.79 per share, for a total transaction of $249,984.00. Following the completion of the transaction, the insider now directly owns 89,600 shares in the company, valued at $249,984. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of NASDAQ OPK opened at $2.69 on Thursday. The business’s 50 day moving average price is $3.23 and its two-hundred day moving average price is $3.67. The company has a market cap of $1.83 billion, a PE ratio of -53.79 and a beta of 1.88. The company has a quick ratio of 2.23, a current ratio of 2.49 and a debt-to-equity ratio of 0.11. OPKO Health, Inc. has a twelve month low of $2.43 and a twelve month high of $5.25.

OPKO Health (NASDAQ:OPKGet Rating) last issued its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). OPKO Health had a negative return on equity of 1.75% and a negative net margin of 1.70%. The firm had revenue of $329.20 million for the quarter, compared to the consensus estimate of $331.45 million. During the same quarter in the prior year, the firm earned $0.05 EPS. The company’s revenue was down 39.6% on a year-over-year basis. As a group, research analysts anticipate that OPKO Health, Inc. will post -0.09 EPS for the current fiscal year.

Several research firms have weighed in on OPK. Piper Sandler reduced their target price on OPKO Health from $6.00 to $5.00 in a report on Tuesday. StockNews.com started coverage on OPKO Health in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. Barrington Research downgraded OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Monday, January 24th. TheStreet downgraded OPKO Health from a “c” rating to a “d+” rating in a research report on Friday, February 25th. Finally, Zacks Investment Research downgraded OPKO Health from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a research report on Monday, January 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.00.

Several large investors have recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of OPKO Health by 5.2% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 58,060 shares of the biotechnology company’s stock worth $212,000 after acquiring an additional 2,854 shares during the period. CIBC Asset Management Inc boosted its stake in shares of OPKO Health by 11.4% in the third quarter. CIBC Asset Management Inc now owns 28,189 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 2,883 shares during the period. Mercer Global Advisors Inc. ADV boosted its stake in shares of OPKO Health by 19.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 19,200 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 3,100 shares during the period. Cetera Advisor Networks LLC boosted its stake in shares of OPKO Health by 33.7% in the first quarter. Cetera Advisor Networks LLC now owns 15,156 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 3,820 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its stake in shares of OPKO Health by 1.1% in the third quarter. UBS Asset Management Americas Inc. now owns 431,092 shares of the biotechnology company’s stock valued at $1,573,000 after buying an additional 4,577 shares during the period. Institutional investors own 27.83% of the company’s stock.

About OPKO Health (Get Rating)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

See Also

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.